Mitsubishi Tanabe Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MITSUBISHI TANABE, and what generic and branded alternatives to MITSUBISHI TANABE drugs are available?
MITSUBISHI TANABE has one approved drug.
Summary for Mitsubishi Tanabe
US Patents: | 0 |
Tradenames: | 1 |
Ingredients: | 1 |
NDAs: | 1 |
Patent Litigation for Mitsubishi Tanabe: | See patent lawsuits for Mitsubishi Tanabe |
Drugs and US Patents for Mitsubishi Tanabe
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mitsubishi Tanabe | RADICAVA | edaravone | SOLUTION;INTRAVENOUS | 209176-002 | Nov 15, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
Mitsubishi Tanabe | RADICAVA | edaravone | SOLUTION;INTRAVENOUS | 209176-002 | Nov 15, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
Mitsubishi Tanabe | RADICAVA | edaravone | SOLUTION;INTRAVENOUS | 209176-001 | May 5, 2017 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Mitsubishi Tanabe
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Mitsubishi Tanabe | RADICAVA | edaravone | SOLUTION;INTRAVENOUS | 209176-001 | May 5, 2017 | 6,933,310 | See Plans and Pricing |
Mitsubishi Tanabe | RADICAVA | edaravone | SOLUTION;INTRAVENOUS | 209176-002 | Nov 15, 2018 | 6,933,310 | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.